Val
—
Gro
—
Qua
—
Mom
—
Sta
—
Cap—
P/S9.27
P/E—
Fwd P/E35.22
PEG0.96
52W— – —
RSI—
Target$70.0 (-2.8%)
Beta1.29
Div0.44%
Loading chart…
RSI (14)
Loading patterns…
Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Spatial Biology. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was incorporated in 1976 and is headquartered in Minneapolis, Minnesota.
52-Week Range
52W Low
—
52W High
Position in Range
—
RSI (14)
0 · Oversold
RSI 74
Overbought · 100
Signal
Overbought
EMA Price Levels
Volume Analysis
Momentum Dashboard
Trend Strength
Detected Patterns
2Bullish
0Bearish
0Neutral
▲ Bull Flag — Breakout after +22% pole — bullish continuation
▲ Bull Flag — Breakout after +47% pole — bullish continuation
View overlays on the price chart via Chart tab → Pattern Overlays.
EPS — History & Forecast
Estimate
Beat
Miss
Forecast
Loading…
Revenue — History & Forecast
Revenue
Forecast
Loading…
EPS Beat Rate
100%
8/8 quarters
Wall Street Consensus
HOLD
BuyHoldSell
Price Target Range
$70.0
-2.8% upside
Low $50
—
High $73
Consensus
Current price
Wall Street Analyst Ratings
| Firm | Rating | Change | Action | Date |
|---|---|---|---|---|
| RBC Capital | Sector Perform | Outperform → Sector Perform | ▼ Downgrade | 2026-07-09 |
| TD Cowen | Hold | Buy → Hold | ▼ Downgrade | 2026-06-30 |
| Benchmark | Hold | Buy → Hold | ▼ Downgrade | 2026-06-30 |
| Citigroup | Neutral | Buy → Neutral | ▼ Downgrade | 2026-06-29 |
| Stephens & Co. | Equal-Weight | Overweight → Equal-Weight | ▼ Downgrade | 2026-06-26 |
| William Blair | Market Perform | Outperform → Market Perform | ▼ Downgrade | 2026-06-26 |
| Baird | Neutral | — | ↔ Maintain | 2026-06-26 |
| Piper Sandler | Neutral | — | ● Initiate | 2026-06-11 |
| Wells Fargo | Overweight | — | ↔ Maintain | 2026-05-07 |
| Evercore ISI Group | In-Line | — | ↔ Maintain | 2026-05-07 |
| Stifel | Hold | — | ↔ Maintain | 2026-02-05 |
| UBS | Buy | — | ↔ Maintain | 2026-02-05 |
| Argus Research | Buy | — | ↔ Maintain | 2025-11-20 |
RBC Capital
2026-07-09
Sector Perform
(from Outperform)
▼ Downgrade
TD Cowen
2026-06-30
Hold
(from Buy)
▼ Downgrade
Benchmark
2026-06-30
Hold
(from Buy)
▼ Downgrade
Citigroup
2026-06-29
Neutral
(from Buy)
▼ Downgrade
Stephens & Co.
2026-06-26
Equal-Weight
(from Overweight)
▼ Downgrade
William Blair
2026-06-26
Market Perform
(from Outperform)
▼ Downgrade
Baird
2026-06-26
Neutral
↔ Maintain
Piper Sandler
2026-06-11
Neutral
● Initiate
Wells Fargo
2026-05-07
Overweight
↔ Maintain
Evercore ISI Group
2026-05-07
In-Line
↔ Maintain
Stifel
2026-02-05
Hold
↔ Maintain
UBS
2026-02-05
Buy
↔ Maintain
Argus Research
2025-11-20
Buy
↔ Maintain
Profitability
Gross Margin
66.40%TTM
Op. Margin
25.19%TTM
ROE
5.34%TTM
Rev. Growth
-1.50%YoY
Free Cash Flow
299.85MTTM
FCF Yield
—TTM
Balance Sheet
Debt / Equity
13.92MRQ
Current Ratio
4.49MRQ
Cash
214.11MMRQ
Total Debt
290.32MMRQ
Net Debt
—MRQ
Income
Div. Yield
0.44%TTM
Annual Rate
0.32Fwd
Payout Ratio
45.71%TTM
Dividend History
Payout Ratio (TTM): 45.71%
| Date | Amount / Share | Yield at Payment |
|---|---|---|
| 2026-05-18 | $0.0800 | 0.18% |
| 2026-02-13 | $0.0800 | 0.13% |
| 2025-11-17 | $0.0800 | 0.14% |
| 2025-08-18 | $0.0800 | 0.15% |
| 2025-05-19 | $0.0800 | 0.16% |
| 2025-02-14 | $0.0800 | 0.12% |
| 2024-11-08 | $0.0800 | 0.11% |
| 2024-08-19 | $0.0800 | 0.11% |
| 2024-05-10 | $0.0800 | 0.10% |
| 2024-02-09 | $0.0800 | 0.12% |
| 2023-11-09 | $0.0800 | 0.14% |
| 2023-08-17 | $0.0800 | 0.10% |
| 2023-05-12 | $0.0800 | 0.10% |
| 2023-02-10 | $0.0800 | 0.11% |
| 2022-11-10 | $0.0800 | 0.10% |
| 2022-08-12 | $0.0800 | 0.09% |
| 2022-05-13 | $0.0800 | 0.09% |
| 2022-02-10 | $0.0800 | 0.08% |
| 2021-11-10 | $0.0800 | 0.07% |
| 2021-08-13 | $0.0800 | 0.07% |
| 2021-05-14 | $0.0800 | 0.08% |
| 2021-02-11 | $0.0800 | 0.08% |
| 2020-11-13 | $0.0800 | 0.11% |
| 2020-08-17 | $0.0800 | 0.12% |
| 2020-05-08 | $0.0800 | 0.12% |
| 2020-02-13 | $0.0800 | 0.16% |
| 2019-11-07 | $0.0800 | 0.16% |
| 2019-08-15 | $0.0800 | 0.17% |
| 2019-05-09 | $0.0800 | 0.16% |
| 2019-02-14 | $0.0800 | 0.18% |
| 2018-11-08 | $0.0800 | 0.19% |
| 2018-08-16 | $0.0800 | 0.18% |
| 2018-05-11 | $0.0800 | 0.22% |
| 2018-02-15 | $0.0800 | 0.24% |
| 2017-11-09 | $0.0800 | 0.27% |
| 2017-08-16 | $0.0800 | 0.28% |
| 2017-05-17 | $0.0800 | 0.31% |
| 2017-02-15 | $0.0800 | 0.32% |
| 2016-11-09 | $0.0800 | 0.33% |
| 2016-08-25 | $0.0800 | 0.32% |
How TECH Makes Its Money
Cash Flow Breakdown
Quarterly Metrics
| Quarter | Revenue | Rev YoY | Gross Profit | Op. Income | Net Income | Net YoY | Gross % | Op % | Net % |
|---|
Full Key Statistics
Valuation
| Market Cap | 11.22B |
| Enterprise Value | 11.35B |
| Trailing P/E | 102.90 |
| Forward P/E | 35.22 |
| PEG Ratio (5yr) | 0.96 |
| Price/Sales (ttm) | 9.27 |
| Price/Book (mrq) | 5.41 |
| EV/Revenue | 9.38 |
| EV/EBITDA | 31.02 |
Share Statistics
| Avg Vol (3m) | 5.01M |
| Shares Outstanding | 155.81M |
| Float | 155.96M |
| % Held by Insiders | 0.31% |
| % Held by Institutions | 117.85% |
| Short Ratio | 1.51 |
| Short % of Float | 8.88% |
Profitability
| Gross Margin | 66.40% |
| Operating Margin (ttm) | 25.19% |
| Profit Margin | 9.05% |
| Return on Assets (ttm) | 7.45% |
| Return on Equity (ttm) | 5.34% |
Income Statement
| Revenue (ttm) | 1.21B |
| Revenue Growth (yoy) | -1.50% |
| Gross Profit (ttm) | 803.97M |
| EBITDA | 366.04M |
| Net Income (ttm) | 109.50M |
| Diluted EPS (ttm) | 0.70 |
| EPS Growth (yoy) | 128.60% |
Balance Sheet
| Total Cash (mrq) | 214.11M |
| Total Debt (mrq) | 290.32M |
| Debt / Equity (mrq) | 13.92 |
| Current Ratio (mrq) | 4.49 |
| Book Value / Share | 13.32 |
| Operating CF (ttm) | 294.86M |
| Free Cash Flow (ttm) | 299.85M |
Trading & Dividends
| Beta (5Y) | 1.29 |
| 50-Day MA | 61.26 |
| 200-Day MA | 59.50 |
| Fwd Dividend Yield | 44.00% |
| Payout Ratio | 45.71% |
Ownership Breakdown
Institutional 117.85%
Insider 0.31%
Short Interest
8.88% of float
High
Institutional 13F Holdings
Famous investors who disclosed a position in TECH in their latest SEC 13F filing.
Loading…
Insider Transactions
| Date | Insider | Role | Transaction | Shares | Value |
|---|---|---|---|---|---|
| 2026-07-23 | BOHNEN SHANE | General Counsel | Conversion of Exercise of derivative security at price 47.60 per share. | 448 | $21,325 |
| 2026-06-02 | CROUSE STEVEN C. | Officer | 600 | — | |
| 2026-05-08 | HERR AMY E. | Director | Sale at price 48.28 per share. | 6,636 | $320,386 |
| 2026-05-08 | HERR AMY E. | Director | Conversion of Exercise of derivative security at price 47.60 per share. | 6,636 | $315,874 |
| 2026-05-05 | BOHNEN SHANE | General Counsel | Conversion of Exercise of derivative security at price 47.60 per share. | 8,400 | $399,840 |
| 2026-05-05 | HIPPEL JAMES | Chief Financial Officer | Conversion of Exercise of derivative security at price 47.60 per share. | 62,000 | $2,951,200 |
| 2026-05-05 | KELDERMAN KIM | Chief Executive Officer | Conversion of Exercise of derivative security at price 47.60 per share. | 26,692 | $1,270,539 |
| 2026-05-01 | CROUSE STEVEN C. | Officer | 794 | — | |
| 2026-04-22 | HIPPEL JAMES | Chief Financial Officer | 62,000 | — | |
| 2026-04-22 | KELDERMAN KIM | Chief Executive Officer | 11,344 | — | |
| 2026-04-14 | KELDERMAN KIM | Chief Executive Officer | Conversion of Exercise of derivative security at price 47.60 per share. | 36,500 | $1,737,400 |
| 2026-04-02 | BOHNEN SHANE | General Counsel | 2,259 | — | |
| 2026-02-17 | HERR AMY E. | Director | Sale at price 59.10 per share. | 1,976 | $116,791 |
| 2026-02-03 | HERR AMY E. | Director | 38 | — | |
| 2026-01-30 | MCMANUS MATTHEW F | Officer | 4,621 | — | |
| 2025-11-03 | HIPPEL JAMES | Chief Financial Officer | 24,704 | — | |
| 2025-11-03 | GEIST WILLIAM | Officer | 9,911 | — | |
| 2025-10-30 | KEEGAN JOSEPH D | Director | Stock Award(Grant) at price 0.00 per share. | 1,640 | — |
| 2025-10-30 | BAUMGARTNER ROBERT V | Director | Stock Award(Grant) at price 0.00 per share. | 1,640 | — |
| 2025-10-30 | BUSHMAN JULIE L. | Director | Stock Award(Grant) at price 0.00 per share. | 1,640 | — |
| 2025-10-30 | VESSEY RUPERT J | Director | Stock Award(Grant) at price 0.00 per share. | 1,640 | — |
| 2025-10-30 | SETH ALPNA | Director | Stock Award(Grant) at price 0.00 per share. | 1,640 | — |
| 2025-10-30 | KLIMOVSKY JUDITH V | Director | Stock Award(Grant) at price 0.00 per share. | 1,640 | — |
| 2025-10-30 | HERR AMY E. | Director | Stock Award(Grant) at price 0.00 per share. | 1,640 | — |
| 2025-10-30 | HIGGINS JOHN L | Director | Stock Award(Grant) at price 0.00 per share. | 1,640 | — |
BOHNEN SHANE
General Counsel
Conversion of Exercise of derivative security at price 47.60 per share.
2026-07-23
448 sh
$21,325
CROUSE STEVEN C.
Officer
2026-06-02
600 sh
—
HERR AMY E.
Director
Sale at price 48.28 per share.
2026-05-08
6,636 sh
$320,386
HERR AMY E.
Director
Conversion of Exercise of derivative security at price 47.60 per share.
2026-05-08
6,636 sh
$315,874
BOHNEN SHANE
General Counsel
Conversion of Exercise of derivative security at price 47.60 per share.
2026-05-05
8,400 sh
$399,840
HIPPEL JAMES
Chief Financial Officer
Conversion of Exercise of derivative security at price 47.60 per share.
2026-05-05
62,000 sh
$2,951,200
KELDERMAN KIM
Chief Executive Officer
Conversion of Exercise of derivative security at price 47.60 per share.
2026-05-05
26,692 sh
$1,270,539
CROUSE STEVEN C.
Officer
2026-05-01
794 sh
—
HIPPEL JAMES
Chief Financial Officer
2026-04-22
62,000 sh
—
KELDERMAN KIM
Chief Executive Officer
2026-04-22
11,344 sh
—
KELDERMAN KIM
Chief Executive Officer
Conversion of Exercise of derivative security at price 47.60 per share.
2026-04-14
36,500 sh
$1,737,400
BOHNEN SHANE
General Counsel
2026-04-02
2,259 sh
—
HERR AMY E.
Director
Sale at price 59.10 per share.
2026-02-17
1,976 sh
$116,791
HERR AMY E.
Director
2026-02-03
38 sh
—
MCMANUS MATTHEW F
Officer
2026-01-30
4,621 sh
—
HIPPEL JAMES
Chief Financial Officer
2025-11-03
24,704 sh
—
GEIST WILLIAM
Officer
2025-11-03
9,911 sh
—
KEEGAN JOSEPH D
Director
Stock Award(Grant) at price 0.00 per share.
2025-10-30
1,640 sh
—
BAUMGARTNER ROBERT V
Director
Stock Award(Grant) at price 0.00 per share.
2025-10-30
1,640 sh
—
BUSHMAN JULIE L.
Director
Stock Award(Grant) at price 0.00 per share.
2025-10-30
1,640 sh
—
VESSEY RUPERT J
Director
Stock Award(Grant) at price 0.00 per share.
2025-10-30
1,640 sh
—
SETH ALPNA
Director
Stock Award(Grant) at price 0.00 per share.
2025-10-30
1,640 sh
—
KLIMOVSKY JUDITH V
Director
Stock Award(Grant) at price 0.00 per share.
2025-10-30
1,640 sh
—
HERR AMY E.
Director
Stock Award(Grant) at price 0.00 per share.
2025-10-30
1,640 sh
—
HIGGINS JOHN L
Director
Stock Award(Grant) at price 0.00 per share.
2025-10-30
1,640 sh
—